Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications

Brian C Cumbie
Kathie L Hermayer
Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, South Carolina, USA

Abstract: Microvascular complications characterized by retinopathy, nephropathy, and neuropathy are highly prevalent among diabetics. Glycemic control has long been the mainstay for preventing progression of these complications; however, such control is not easily achieved. Currently, alternative adjunctive approaches to treating and preventing microvascular damage are being undertaken by targeting the molecular pathogenesis of diabetic complications. This review summarizes the specific pathogenic mechanisms of microvascular complications for which clinical therapies have been developed, including the polyol pathway, advanced glycation end products, protein kinase c, vascular epithelium growth factor, and the superoxide pathway. The review further focuses on therapies for these targets that are currently available or are undergoing late-stage clinical trials.

Keywords: diabetes, aldose reductase inhibitor, advanced glycation end products, protein kinase C inhibitor, vascular epithelium growth factor inhibitor, antioxidants

Introduction

Diabetes is estimated to have affected 171 million people worldwide in 2006 and is projected to affect 366 million by 2030 (The World Health Organization 2007). It was the 5th leading cause of death in 2000, and diabetic microvascular complications account for a significant portion of the morbidity and mortality (Roglic et al 2005). Diabetic retinopathy, nephropathy, and neuropathy are the leading causes of blindness, end-stage renal disease, and amputations in the US (American Diabetes Association 2007). Although type 1 and type 2 diabetes originate from different pathogenetic causes, there is a significant association between hyperglycemia and the diabetic microvascular complications in both type 1 and type 2 diabetes (The Diabetes Control and Complications Trial Research Group 1993; UK Prospective Diabetes Study (UKPDS) Group 1998). In the past decade, large, long-term prospective trials involving treatment and control of hyperglycemia in type 1 and 2 diabetics have shown microvascular related morbidity can be significantly reduced but not entirely prevented through long-term glycemic and blood pressure control (The Diabetes Control and Complications Trial Research Group 1993; UK Prospective Diabetes Study (UKPDS) Group 1998). Newer strategies to ameliorate or prevent microvascular complications involve a molecular understanding of diabetic complications.

Overview

The pathologic mechanisms underlying the susceptibility of retinal capillary endothelial, renal glomeruli mesangial, and neural tissues to chronic hyperglycemia has been studied over the past century. With the 1966 discovery of the polyol pathway, a number of pathogenic mechanisms have been described including advanced glycation...
Aldose reductase inhibitors and the polyol pathway

The polyol pathway reduces toxic aldehydes generated by ROS to inactive alcohols (Figure 1) (Brownlee 2001; Sheetz and King 2002). Aldose reductase (AR), via the consumption of NADPH, is responsible for the initial and rate-limiting step in the process. Glucose can be reduced to sorbitol, and eventually fructose, through this pathway, but AR has a low affinity for glucose at normal concentrations. Elevated intracellular glucose can increase AR activity, resulting in significantly decreased NADPH. NADPH is also required for glutathione reductase activity, which reduces glutathione (GSH)—a major mechanism for reducing intracellular oxidative stress (Lee and Chung 1999). Decreased NADPH and resulting decreased GSH reductase activity ultimately increases oxidative stress and activates pathways that increase cellular damage.

Aldose reductase inhibition (ARI) is ostensibly an ideal target for reducing the deleterious effects associated with polyol pathway activation. However, clinical trials with ARIs have shown lack of efficacy or adverse effects. In the 1980’s, sorbinil became the first ARI to undergo clinical trials after promising preclinical results. Results from several studies on neuropathy were mixed, but the majority suggested a lack of significant effects (Jaspan et al 1986; Martyn et al 1987; Guy et al 1988; Sorbinil Retinopathy Trial Research Group 1993). Sorbinil was evaluated for treating retinopathy and nephropathy in the early 1990’s but again showed a lack of efficacy (Sorbinil Retinopathy Trial Research Group 1990; Sorbinil Retinopathy Trial Research Group 1993). Hypersensitivity reactions, occurring at increased doses, further limited the agent’s effectiveness.

Subsequent clinical evaluation of ARIs such as tolrestat or lidorestat were halted due to toxicities before their efficacy could be definitively evaluated (Foppiano and Lombardo 1997). Others such as ponarrestat and zopolrestat were ineffective despite having more favorable side effect profiles (Sundkvist et al 1992). Zenarestat improved nerve conduction velocity and nerve morphology in a rigorous, year-long randomized, placebo-controlled trial (Greene et al 1999). However, further Phase 3 studies were eventually halted due to significant creatinine elevations in study participants (Brown et al 2004).

Epalrestat was the first successful ARI to be developed and was approved for use in Japan in 1992 for treatment of diabetic peripheral neuropathy. Randomized, double blinded, placebo-controlled trials of 12 and 24 weeks in diabetics with mild neuropathy suggested improved nerve conduction, vibration thresholds, and symptoms (Goto et al 1995; Uchida et al 1995). Improvement in peripheral neuropathy and minimal side effects were observed in a prospective observational study of more than 5,000 diabetics treated over 3–12 months (Hotta et al 1996). Smaller long-term studies have also suggested the utility of epalrestat in ameliorating autonomic neuropathies related to cardiac function and gastric and esophageal motility (Ikeda et al 1999; Nakayama et al 2001; Okamoto et al 2003; Kinekawa et al 2005). Epalrestat’s effects on nephropathy were evaluated via a placebo-controlled, randomized trial over 5 years. Thirty-five type 2 diabetics with baseline microalbuminuria were studied, and microalbuminuria was found to be unchanged in...
the treatment group, but significantly increased in the placebo arm suggesting a benefit in treating nephropathy (Iso et al 2001). Recently, a 3-year randomized controlled trial involving 594 diabetics with mild to moderate neuropathy again showed that epalrestat was effective in improving median nerve conduction, vibration perception threshold, and symptoms without severe adverse effects (Hotta et al 2006). The study also showed a statistical difference in improvement and progression of retinopathy, although not microalbuminuria, between control and treatment groups. Cardiac autonomic effects were positive but not significant.

Two new ARIs, fidarestat and ranirestat, have more recently been evaluated in safety and efficacy studies in a randomized, double-blinded, placebo-controlled trial in the US and Japan in which 279 diabetics were studied (Hotta et al 2001). Improvement in peripheral neuropathy, as evaluated by electrophysiological nerve studies and symptom reports, was statistically significant compared to placebo with no difference in adverse effects between study and placebo groups. No data were reported regarding retinopathy or nephropathy. In 2004, Phase 2 trials were halted despite the positive results due to corporate restructuring of the trial sponsor. Whether evaluation of fidarestat will be resumed is unclear.

Ranirestat effectively penetrates peripheral nerves and has shown encouraging effects on peripheral neuropathy at both 5 mg and 20 mg doses in a 12-week, double-blinded, placebo-controlled trial (Bril and Buchanan 2004). A 48-week extension trial involving 86 of the participants continued the evaluation of nerve conduction studies, vibration perception thresholds, and neuropathic symptoms as assessed by the Toronto clinical neuropathy score (Bril and Buchanan 2006). The placebo arm participants were given low-dose ranirestat (5 mg) and the other treatment groups continued with their prior doses of 5 and 20 mg. Further declines in nerve conduction were prevented and a statistically significant improvement was observed in nerve conduction and symptoms by the study’s end. Although the extension was not sufficiently powered or placebo controlled, the results are encouraging and must be validated in future trials. Phase 3 trials for ranirestat were completed in the US in December 2006, and publication of results are currently pending.

**Inhibitors of AGEPs**

AGEPs are a heterogeneous group of modified proteins, lipids, and nucleic acids implicated in the aging process and diabetes. In intracellular hyperglycemia, these products are formed primarily through nonenzymatic reactions (Maillard reactions) between amino groups and glucose or highly reactive glucose derivatives known as dicarbonyls (Figure 2) (Brownlee 2001). Hyperglycemia may also drive AGEP formation through polyol pathway-derived intermediates and oxidative stress (Hamada et al 1996). AGEPs alter intracellular and extracellular proteins and their functions (Brownlee 2001; Goldin et al 2006; Huebschmann et al 2006). Receptors for AGEPs (RAGE) may also bind AGEPs causing the NF-κB-mediated activation of various cytokines, pro-coagualtory and pro-inflammatory factors, and increased vascular permeability (Brownlee 2001; Goldin et al 2006; Huebschmann et al 2006).

Studies in diabetic populations show AGEPs correlate with the development and severity of retinopathy, neuropathy, and nephropathy as well as macrovascular complications (Monnier et al 2005). RAGE also exists in a soluble state (sRAGE) within the circulation and is thought to clear AGEP from the circulation, thereby preventing the binding of cellular targets (Katakami et al 2005). Type 2 diabetics have lower sRAGE levels compared to nondiabetics, suggesting a downregulation of sRAGE in hyperglycemia. Strategies to prevent AGEP effects, aside from glycemic control, include decreasing exogenous AGEP intake, inhibiting AGEP formation, disrupting AGEP cross-links, enhancing removal of AGEPs, and reducing oxidative stress.

Approximately 10% of exogenous AGEPs and their precursors consumed through diet are absorbed through the intestinal epithelium (Goldberg et al 2004). Foods with high AGE content include meat, meat substitutes, high-fat foods, and foods cooked for prolonged periods or cooked at high temperatures (broiling, roasting, or frying). Conversely, fruits, vegetables, complex carbohydrates, lower temperature cooking methods, shorter cooking duration, or methods employing higher water contents (ie, boiling) are associated with lower AGE levels. Clinical studies in human diabetics are limited but do show increased circulating AGEP levels and markers of inflammation associated with increased dietary intake (Goldberg et al 2004; Uribarri et al 2005). Exogenous AGEPs are also increased through tobacco smoking – smoking cessation reduces exogenous AGEPs (Cerami et al 1997).

Aminoguanidine, the first targeted AGEP therapy, is a hydrazine derivative that prevents AGEP formation by binding reactive carbonyl intermediates (Thornalley 2003). Aminoguanidine’s effects on nephropathy and retinopathy in 690 type 1 diabetics were evaluated in a randomized, double-blinded, placebo-controlled trial. Progression of glomerular filtration rate (GFR) decline, proteinuria, and retinopathy was significantly improved, although 3 patients given high-dose aminoguanidine developed glomerulonephritis (Bolton et al 2004). A similar
A newer agent, alagebrum chloride (ALT-711) cleaves AGE precursors and protein cross-links thereby facilitating AGE clearance. Two clinical trials with mixed diabetic and non-diabetic populations with atherosclerosis and heart failure reveal that ALT-711 can improve vascular and left ventricular compliance with adverse effects similar to placebo (Kass et al 2001; Little et al 2005). In animal studies, ALT-711 was beneficial in treating diabetic renal complications (Forbes et al 2003); however, no clinical studies to date have evaluated its effects on the microvascular system.

The effects of two B vitamins on AGEs have also been clinically studied in humans. The highly bioavailable thiamine derivative, benfotiamine, was studied in 13 diabetics who consumed an AGE-rich meal (Stirban et al 2006). Postprandial AGE levels and markers of endothelial dysfunction were significantly decreased after benfotiamine was administered for 3 days. Benfotiamine has also been shown to improve the symptoms of diabetic neuropathy in 2 studies in which AGEs were not measured (Winkler et al 1999; Haupt et al 2005). A combination of benfotiamine and pyridoxine (as well as vitamin B12) have been studied in both diabetic and alcoholic neuropathy and both improved symptoms and nerve conduction velocity, although AGE effects were not specifically evaluated (Stracke et al 1996; Woelk et al 1998). Pyridoxamine is proposed to improve AGEP-related complications through dicarbonyl clearance, prevention of oxidative damage, and prevention of AGEP formation (Voziyan and Hudson 2005). A Phase II randomized, double-blinded, placebo-controlled trial with 128 diabetics with nephropathy, most of whom were on ACE or ARB therapy, revealed significantly decreased rates of creatinine elevations and albuminuria that was especially marked among those with more advanced disease (Williams et al 2003). Adverse events did not include neurotoxicities and were similar to placebo (Williams 2006).

In additional studies, AGEs have been evaluated in diabetes, hypertension, and lipid modulation. Epalrestat has been shown to reduce serum AGEs in diabetics after 2–3 months of use (Nakamura et al 2003; Hamada et al 2000). AGE modulation by metformin was compared to insulin, sulfonyureas, or insulin plus sulfonyureas in type 2 diabetics with similar glycemic control and no renal impairment (Beisswenger et al 1999). Metformin was superior in reducing reactive dicarbonyl precursors compared to insulin or sulfonyureas in any combination independent of glycemic control. In type 1 diabetics, perindopril has been shown to increase soluble RAGE, an endogenous RAGE clearance mechanism, and decrease low molecular weight AGEs over 2 years when compared to nifedipine (Forbes et al 2005). In contrast, the ARB, irbesartan, did not affect AGEs in a separate clinical evaluation (Persson et al 2006). Simvastatin treatment and adherence to an American Heart Association

---

**Figure 2** Mechanisms by which intracellular production of advanced glycation end-product (AGE) precursors damages vascular cells. Covalent modification of intracellular proteins by dicarbonyl AGE precursors alters several cellular functions. Modification of extracellular matrix proteins causes abnormal interactions with other matrix proteins and integrins. Modification of plasma proteins by AGE precursors creates ligands that bind to AGE receptors, inducing changes in gene expression in endothelial cells, mesangial cells and macrophages (Brownlee 2001) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).
diet for 4 months also has been shown to decrease cellular RAGE in carotid plaques of type 2 diabetics independent of glycemic control versus dietary modifications alone (Cuccurullo et al 2006). None of these studies specifically evaluated microvascular indices and further clinical trials are needed to confirm potential outcome benefits.

**Diacylglycerol PKC inhibition**

The PKC family consists of a group of 12 serine/threonine kinases involved in intracellular signaling related to a variety of vascular, cardiac, immunologic, and other systemic functions (Mellor and Parker 1998; Sheetz and King 2002). Diacylglycerol (DAG) is an upstream activator in the majority of PKC isoforms (Koya and King 1998; Inoguchi et al 1992). *De novo* DAG formation increases with elevated intracellular glucose with a resultant increase of primarily PKC-β1/2 and PKC-δ isoform activity (Figure 3) (Koya and King 1998). PKC may also be activated by growth factors, and hyperglycemia-induced superoxide and AGE formation (Koya and King 1998; Sheetz and King 2002).

PKC-β1 and 2 are chiefly responsible the deleterious effects on retinal, neural, and renal tissues (Inoguchi et al 1992; Shiba et al 1993; Craven et al 1990). These isoforms impair retinal and renal blood flow, and increase capillary leakage (Feke et al 1994). PKC-induced increased extracellular matrix production and upregulation of various inflammatory cytokines further damage the macro and microvascular systems (Craven et al 1997).

PKC412, while not exclusively a PKC inhibitor, was the first PKC inhibitory agent to undergo clinical evaluation in a randomized, double-blinded, placebo-controlled trial (Camposchioaro et al 2004). While effective in treating diabetic macular edema, further studies of PKC412 were abandoned due to hepatotoxicity. Ruboxistaurin is a selective PKC-β inhibitor that has been shown to improve retinal circulation parameters and decrease diabetic macular edema retinal leakage without significant adverse effects (Strom et al 2005; Aiello et al 2006a). In clinical trials to control progression of retinopathy, ruboxistaurin’s results are mixed. In a randomized, double blinded placebo-controlled study (PKC-DRS) of 192 diabetics with moderate to severe nonproliferative retinopathy treated with various doses of ruboxistaurin, retinopathic progression did not decrease over a period of up to 4 years, although moderate vision loss was significantly decreased in the high-dose (32 mg) treatment group (The PKC-DRS Study Group 2005). In a subgroup with macular edema, additional vision loss was prevented in the high-dose treatment group versus placebo, and adverse effects were similar to placebo. In the follow up study (PKC-DRS 2), 685 diabetics with macular edema for 36 months were assessed for the prevention of sustained vision loss as the primary end point. As in the prior studies, ruboxistaurin (32 mg) prevented progression of sustained moderate visual loss with a relative risk reduction of 45% versus placebo (Aiello et al 2006b). Also, significant prevention of macular edema progression and a decreased need for initial photoagulation was observed.

---

**Figure 3** Consequences of hyperglycemia-induced activation of protein kinase C (PKC). Hyperglycemia increases diacylglycerol (DAG) content, which activates PKC, primarily the β- and δ- isoforms. Activation of PKC has a number of pathogenic consequences by affecting expression of endothelial nitric oxide synthetase (eNOS), endothelin-1 (ET-1), VEGF, TGF-β, and plasminogen activator inhibitor-1 (PAI-1), and by activating NF-κB and NAD(P)H oxidases (Brownlee 2001) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).
in the treatment group; although, retinopathic progression was not affected.

A recent randomized, double-blinded, placebo-controlled trial of 123 diabetics with albuminuria who were taking ACE or ARB therapy indicated that ruboxistaurin reduces albuminuria:creatinine ratios versus placebo (Tuttle et al 2005). GFR was also preserved relative to baseline in the treatment group, but this study was not of sufficient statistical power to compare GFR trends between treatment and placebo groups. The effect of ruboxistaurin on diabetic peripheral neuropathy (DPN) has also been evaluated in a 1-year randomized, double-blinded, placebo-controlled trial of 205 diabetics (Vinik et al 2005). While participants with symptomatic DPN showed significant improvement of symptoms, only a subgroup with less severe baseline features showed significant improvement of their vibration detection threshold and symptoms. Ruboxistaurin is currently pending FDA approval for the treatment of diabetic macular edema.

**VEGF inhibitors**

VEGF is a glycoprotein whose production is increased in hyperglycemia, primarily through the PKC pathway. VEGF mediates its effects on the retina through the receptor tyrosine kinases VEGFR-1 and VEGFR-2 (Shen et al 1993; Ferrara 2004). In turn, angiogenesis is stimulated and capillary permeability and leakage are increased (Shen et al 1993; Dvorak et al 1995; Ferrara 2004). Vitreous VEGF levels reflect the severity of neovascularization in diabetic retinopathy and decline with photocoagulation (Aiello et al 1994; Funatsu et al 2006). Experimental data suggests there are similar elevations in renal tissue although the pathogenesis is less well established (Hohenstein et al 2006).

Systemic therapies against VEGF are impractical as VEGF is vital in processes such as angiogenesis in the myocardium and wound healing (van Wijngaarden et al 2005). Intraocular injections of VEGF inhibitors represent a method of targeted therapy that would avoid the adverse systemic effects. Three drugs are currently being studied in clinical settings: pegaptanib, ranizumab, and bevacizumab.

Pegaptanib sodium is an anti-VEGF aptamer which binds VEGF and prevents it from interacting with its receptors (Gragoudas et al 2004). Two concurrent, prospective, double-blinded, randomized, sham-controlled trials in patients with non-diabetic age related macular edema suggest that have intraocular injections at 6-week intervals over the course of 48 weeks slow visual loss (Gragoudas et al 2004). In diabetics, a similarly designed study over 36 weeks showed that pegaptanib improved visual acuity outcomes, preserved central retinal thickness, and required less photocoagulation therapy in 172 participants with baseline diabetic macular edema (Cunningham Jr et al 2005). Adverse events were similar among treatment and control groups, although 8% of all participants experienced a severe adverse event, and 16 of the participants also had baseline retinal neovascularization and were subsequently followed for neovascular progression in a separate study (Adamis et al 2006). Pegaptanib led to regression in 62% of treated eyes versus 0% of the control group.

Ranizumab and bevacizumab are recombinant humanized monoclonal antibody fragments and full-length antibodies, respectively (Steinbrook 2006). Both agents are derived from the same mouse monoclonal antibody precursor and show high affinity for VEGF, neutralizing its effects by binding to VEGF and preventing VEGFR interaction. Bevacizumab was originally designed for intravenous injection as a chemotherapeutic against metastatic colorectal cancer, but it has been adapted for off-label use as an intraocular injection similar to ranizumab (Hurwitz et al 2004; Rosenfeld 2006a). Several case series and studies have also suggested bevacizumab to be safe and effective in decreasing retinal neovascularization and macular edema in diabetics (Avery et al 2006; Haritoglou et al 2006; Jorge et al 2006; Mason et al 2006; Oshima et al 2006; Spaide and Fisher 2006). Two large prospective randomized studies have recently been completed in which ranizumab was assessed for treatment of nondiabetic, age-related macular edema (Brown and Kaiser 2006; Rosenfeld et al 2006b). The studies show ranizumab to be superior in improving visual acuity and regression of neovascularization with a low incidence of serious adverse events over 1 year versus either sham injection or verteporfin photodynamic therapy. In a 2-year pilot study in 10 diabetics with clinically significant macular edema, similar findings of improved visual acuity and central retinal thickness were observed, and safety was not a concern (Chun et al 2006).

The new VEGF inhibitors show promise in targeting diabetic retinopathy, but are cost-prohibitive (Steinbrook 2006), and no trials have indicated that one is superior to the others. Additionally, systemic effects have been noted in the intraocular preparations (Jorge et al 2006). Bevacizumab, in particular, has been investigated in this regard due to its longer half life (Steinbrook 2006). Finally, the question of whether prolonged inhibition of VEGF may actually further retinal deterioration remains to be answered (Csaky 2003).
Antioxidant therapy and ROS

ROS are end products of pathogenic pathways as well as the hexosamine pathway and they are the cause of diabetic microvascular injury. ROS have long been targeted in therapeutic trials for diabetic microvascular complications. A detailed review of antioxidants is beyond the scope of this paper, but clinical studies of diabetics who were supplemented with traditional antioxidants (vitamins C and E) indicated that markers of oxidative stress were alleviated microvascular complications were not prevented or improved (Lonn et al 2002; Scott and King 2004; Liu et al 2006).

Our understanding of the roles of oxygen free radicals in diabetic complications has recently evolved with the description of the super oxide pathway (Brownlee 2001). In hyperglycemia, experimental endothelial cells have increased flux of glucose through glycolysis, pyruvate decarboxylation, and the citric acid cycle resulting in mitochondrial electron transport chain overload (Nishikawa et al 2000). In turn, overloaded mitochondria produce excessive superoxide anions which ultimately lead to decreases in nitric oxide, DNA damage, AGE formation, and activation of the polyol, PKC, and hexosamine pathways as well as activation of poly (ADP-ribose) polymerase (Figure 4) (Du et al 2000; Nishikawa et al 2000; Brownlee 2001).

The realization that ROS both contribute to induction of major pathways of diabetic complications and comprise the pathway’s end products may explain why traditional antioxidants have failed. Vitamin E and others antioxidants act primarily to non-enzymatically scavenge certain end-product ROS thereby limiting their effects to only a portion of the damaging end-product (Du et al 2000). Currently used agents for diabetic microvascular control, including thiazolidinediones, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and statins are believed to derive some of their benefit from modulating superoxides (Ceriello 2003). To improve the effect of antioxidant therapy, compounds are being studied that specifically act against superoxide and prevent induction of the various pathogenic mechanisms.

α-lipoic acid is one such compound that has received the most attention in clinical trials, which indicated that it can reduce markers of oxidation in poorly controlled diabetics and in patients with metabolic syndrome (Borcea et al 1999; Sola et al 2005). A meta analysis of 4 randomized, double-blinded, placebo-controlled, 3-week trials of 1,258 diabetics showed that 600 mg of α-lipoic acid significantly improved measures of DPN (Ziegler et al 2004). More recently, a randomized, double-blinded, placebo-controlled trial of 182 type 1 and 2 diabetics were treated with α-lipoic acid (600–1800 mg) over 5 weeks was conducted to evaluate the effects on DPN (Ziegler et al 2006). All treated groups had significantly improved pain and neuropathy as assessed by a total symptom score (TSS), a neuropathy impairment score, and a neuropathy and symptoms and change score (NCS). Nerve conduction studies and symptoms of numbness and parasthesia did not significantly improve and dose-related nausea, vomiting, and vertigo were noted with treatment. No clinical data exist regarding treatment of diabetic retinopathy, although at least one study assessed its effects on nephropathy. A prospective non-randomized, open, placebo-controlled study of 84 type 1 and 2 diabetics was conducted to evaluate the effect of α-lipoic acid over 18 months (Morcos et al 2001). Urinary albuminuria was increased in the placebo group but unchanged in the treatment group.

Conclusion

Greater understanding of diabetic pathophysiology is yielding promising results by guiding the development of these new targeted therapies. Agents such as epalrestat, ruboxistaurin, ranizumab, and α-lipoic acid have been well studied and are now or soon to be available in certain countries. The newer ARI and AGE therapies require further large-scale trials to verify their efficacy, but the initial results are encouraging. While not covered here, other notable new therapies that do not necessarily target specific diabetic pathophysiologic mechanisms such as glycosaminoglycan sulodexide.
for nephropathy, intraocular steroids for retinopathy, or monochromatic near-infrared treatment for neuropathy are also showing benefit (Solini et al 1997; Gambaro et al 2002; Simpson et al 2004; Sutter et al 2004; Achour et al 2005; Clift et al 2005; Gillies et al 2006). These new therapies are likely to represent a significant change in the management of diabetic retinopathy, nephropathy, and neuropathy beyond glycemic and blood pressure control.

References

Achour A, Kacem M, et al. 2005. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol, 18:568–74.

Adams AP, Altaweel M, et al. 2006. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology, 113:23–8.

Aiello LP, et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med, 331:1480–7.

Aiello LP, Clermont A, et al. 2006. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci, 47:86–92.

Aiello LP, Davis MD, et al. 2006. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113:2221–30.

American Diabetes Association. 2007. All about diabetes [online]. Accessed 25 February 2007. URL: http://www.diabetes.org/about-diabetes.jsp

Avery RL, Pearlman J, et al. 2006. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology, 113:e1–15.

Beisswenger PJ, Howell SK, et al. 1999. Metformin reduces systemic methyglyoxal levels in type 2 diabetes. Diabetes, 48:198–202.

Bolton WK, Cattran DC, et al. 2004. Randomized trial of an inhibitor of advanced glycation end products in diabetic nephropathy. Am J Nephrol, 24:32–40.

Bordea V, Nourooz-Zadeh J, et al. 1999. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med, 26:1495–500.

Bril V, Buchanan RA. 2004. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care, 27:2369–75.

Bril V, Buchanan RA. 2006. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care, 29:68–72.

Brown MJ, Bird SJ, et al. 2004. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care, 27:1153–9.

Brown DM, Kaiser P. 2006. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 355:1432–44.

Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414:813–20.

Brownlee M. 2005. The pathology of diabetic complications: a unifying mechanism. Diabetes, 54:1615–25.

Campochiaro PA, C99-PKC412-003 Study Group. 2004. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci, 45:922–31.

Cerami C, Founds H, et al. 1997. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA, 94:13915–20.

Ceriello A. 2003. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care, 26:1589–96.

Chun DW, Heier JS, et al. 2006. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology, 113:1706–12.

Clift JK, Kasser RJ, et al. 2005. The effect of monochromatic infrared energy on sensation in patients with diabetic peripheral neuropathy: a double-blind, placebo-controlled study. Diabetes Care, 28:2896–900.

Craven PA, Davidson CM, et al. 1990. Increase in diacetylglcerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes, 39:667–74.

Craven PA, Studer RK, et al. 1997. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes, 46:671–81.

Csaky K. 2003. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology, 110:879–81.

Cuccurullo C, Lezzi A, et al. 2006. Suppression of RAGE as a basis of simvastatin-dependent plate stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol, 26:2716–23.

Cunningham ET Jr, et al. 2005. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 112:1747–57.

The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:977–86.

Du XL, Edelstein D, et al. 2000. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Spi1 glycosylation. Proc Natl Acad Sci USA, 97:12222–6.

Dvorak HF, Brown LF, et al. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146:1029–39.

Feke GT, Buzzney SM, et al. 1994. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci, 35:2968–75.

Ferrara N. 2004. Vascular endothelial growth factor: basic science and clinical progress. Endo Rev, 25:581–611.

Foppiano M, Lombardo G. 1997. Worldwide pharmacovigilance systems and tolfestat withdrawal. Lancet, 349:399–400.

Forbes JM, Thallas V, et al. 2003. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J, 17:1762–4.

Forbes JM, Thorpe SR, et al. 2005. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol, 16:2363–72.

Freedman BI, Wuerth JP, et al. 1999. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials, 20:493–510.

Funatsu H, Yamashita H, et al. 2006. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 113:294–301.

Gambino R, Kinliska I, et al. 2002. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol, 13:1615–25.

Gillies MC, Sutter FK, et al. 2006. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology, 113:1533–8.

Goldberg T, Cai W, et al. 2004. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc, 104:1287–91.

Goldin A, Beckman JA, et al. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114:597–605.

Goto Y, Hotta N, et al. 1995. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother, 49:269–77.

Gragoudas ES, Adamis AP, et al. 2004. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 351:2805–16.

Greene DA, Brown MB. 1999. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology, 53:580–91.
Guy RJ, Gilbey SG, et al. 1988. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. *Diabetologia*, 4:214–20.

Hamada Y, Araki N, et al. 1996. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. *Biochem Biophys Res Commun*, 226:539–43.

Hamada Y, Nakamura J, et al. 2000. Epalrestat, an aldose reductase inhibitor, reduces the levels of Neptilion-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. *Diabetes Care*, 23:1539–44.

Haringhoul C, Kook D, et al. 2006. Intravital real bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. *Retina*, 26:999–1005.

Haupt E, Ledermann H, et al. 2005. Benfotiamine in the treatment of diabetic polyneuropathy – a three-week randomized, controlled pilot study (BEDIP study). *Int J Clin Pharmacol Ther*, 43:71–7.

Hohenstein B, Hausknecht B, et al. 2006. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. *Kidney Int*, 69:1654–61.

Hotta N, Sakamoto N, et al. 1996. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic nephropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. *J Diabetes Complications*, 10:168–72.

Hotta N, Toyota T, et al. 2001. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. *Diabetes Care*, 24:1776–82.

Hotta N, Akanuma Y, et al. 2006. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. *Diabetes Care*, 29:1538–44.

Huebschmann AG, Regensteiner JG, et al. 2006. Diabetes and advanced glycation end products. *Diabetes Care*, 29:1420–2.

Hurwitz H, Fehrenbacher L, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*, 350:2335–42.

Ikeda T, Iwata K, et al. 1999. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. *Diabetes Res Clin Pract*, 43:193–8.

Inaguchi T, Battan R, et al. 1992. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. *Proc Natl Acad Sci USA*, 89:11059–63.

Iso K, Tada H, et al. 2001. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. *Diabetes Complications*, 15:241–4.

Jaspan JB, Towle VL, et al. 1986. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. *Metabolism*, 35:83–92.

Jorge R, Costa RA, et al. 2006. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBBEPE study). *Retina*, 26:1006–13.

Kass DA, Shapiro EP, et al. 2001. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. *Circulation*, 104:1464–70.

Katakami N, Matsuha M, et al. 2005. Decreased endogenous secretory advanced glycation end and product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. *Diabetes Care*, 28:2716–21.

Kinekawa F, Kubo F, et al. 2005. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients. *Hepatogastroenterology*, 52:471–4.

Koya D, King GL. 1998. Protein kinase C activation and the development of diabetic complications. *Diabetes*, 47:859–66.

Lee AJ, Chung SS. 1999. Contributions of polyol pathway to oxidative stress in diabetic cataract. *FASEB J*, 1:23–30.

Leonard DR, Farooqi MH, et al. 2004. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. *Diabetes Care*, 27:168–72.

Little WC, Zile MR, et al. 2005. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. *J Card Fail*, 11:191–5.

Liu S, Lee IM, et al. 2006. Vitamin E and risk of type 2 diabetes in the women’s health study randomized controlled trial. *Diabetes*, 55:2856–62.

Lonn E, Yusuf S, Hoogwerf B, et al. 2002. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. *Diabetes Care*, 25:1919–27.

Martyn CN, Reid W, et al. 1987. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. *Diabetes*, 36:987–90.

Mason 3rd JO, Nixon PA, et al. 2006. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. *Am J Ophthalmol*, 142:685–8.

Mellor H, Parker PJ. 1998. The extended protein kinase C superfamily. *Biochem J*, 1:281–92.

Morcos M, Borcea V, et al. 2001. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. *Diabetes Res Clin Pract*, 52:175–83.

Monnier VM, Sell DR, et al. 2005. Glycation products as markers and predictors of the progression of diabetic complications. *Ann N Y Acad Sci*, 1043:567–81.

Nakamura N, Yamazaki K, et al. 2003. Effects of epalrestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. *In Vivo*, 17:177–80.

Nakayama M, Nakamura J, et al. 2001. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. *Diabetes Care*, 24:1093–8.

Nishikawa T, Edelstein D, et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*, 404:787–90.

Okamoto H, Nomura M, et al. 2003. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. *Intern Med*, 42:655–64.

Oshima Y, Sakaguchi H, et al. 2006. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. *Am J Ophthalmol*, 142:155–8.

Persson F, Rossing P, et al. 2006. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. *Diabetes*, 55:3550–5.

Roglic G, Unwin N, et al. 2005. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care*, 9:2130–5.

Rosenfeld PJ. 2006. Intravitreal avastin: the low cost alternative to lucentis?. *Am J Ophthalmol*, 142:141–3.

Rosenfeld PJ, Brown D, et al. 2006. Ranibizumab for Neovascular Age-Related Macular Degeneration. *N Engl J Med*, 355:1419–31.

Scott JA, King GL. 2004. Oxidative stress and antioxidant treatment in diabetes. *Ann N Y Acad Sci*, 1031:204–13.

Sheehtz MJ, King GL. 2002. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. *JAMA*, 288:2579–88.

Shen H, Clauss M, et al. 1993. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on monocellular phagocytes. *Blood*, 81:2767–73.

Shiba T, Inoguchi T, et al. 1993. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. *Circulation*, 103:1199–1203.

Sola S, Mir MQ, et al. 2005. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. *Circulation*, 111:343–8.

Solini A, Vergnani L, et al. 1997. Glycosaminoglycans delay the progression of nephropathy in NIDDM. *Diabetes Care*, 20:819–23.
Sorbinil Retinopathy Trial Research Group. 1990. Randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. *Arch Ophthalmol*, 108:1234–44.

Sorbinil Retinopathy Trial Research Group. 1993. The sorbinil retinopathy trial: neuropathy results. *Neurology*, 43:1141–9.

Spaide RF, Fisher YL. 2006. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. *Retina*, 26:275–8.

Steinbrook R. 2006. The price of sight – ranibizumab, bevacizumab, and the treatment of macular degeneration. *N Engl J Med*, 355:1409–12.

Stirban A, Negrean M, et al. 2006. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. *Diabetes Care*, 29:2064–71.

Stracke H, Lindemann A, et al. 1996. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. *Exp Clin Endocrinol Diabetes*, 104:311–16.

Strom C, Sander B, et al. 2005. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. *Invest Ophthalmol Vis Sci*, 46:3855–8.

Sundkvist G, Armstrong FM, et al. 1992. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. *J Diabetes Complications*, 6:123–30.

Sutter FK, Simpson JM, et al. 2004. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. *Ophthalmology*, 111:2044–9.

The PKC-DRS Study Group. 2005. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. *Diabetes*, 54:2188–97.

Thornalley PJ. 2003. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. *Arch Biochem Biophys*, 419:31–40.

Tuttle KR, Bakris GL, et al. 2005. The effect of ruboxistaurin on nephropathy in type 2 diabetes. *Diabetes Care*, 28:2686–90.